Previous Close | 4.2700 |
Open | 4.2600 |
Bid | 0.0000 x 1400 |
Ask | 0.0000 x 800 |
Day's Range | 4.1400 - 4.3800 |
52 Week Range | 2.0100 - 12.1500 |
Volume | |
Avg. Volume | 720,325 |
Market Cap | 195.915M |
Beta (5Y Monthly) | 0.63 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.8450 |
Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 26.14 |
Subscribe to Yahoo Finance Plus to view Fair Value for BCAB
If you want to know who really controls BioAtla, Inc. ( NASDAQ:BCAB ), then you'll have to look at the makeup of its...
Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in PD-1 failure NSCLC continues to show strong antitumor activity in a highly refractory population with additional patients enrolled BA3011 Undifferentiated Pleomorphic Sarcoma (UPS) Phase 2 part 2 of the potentially registrational study is being initiated; anticipate first patient dosed this quarter BA3071 Phase 1 study ongoing with first two dose escalation cohorts completed; third cohort (70mg) on-going CAB clinical programs continue
Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Scott A. Smith and Elisha W. Finney have been appointed as Viatris' newest members of its board of directors. Smith and Finney fill the vacancies created by the retirement of Neil Dimick and Ian Reid.